editorials · reviews · multicenter studies · meta-analyses · randomized controlled trials · retractions
Clin. Pharmacol. Ther. · Aug 2016
This commentary focuses on the status of oral anticoagulants, namely, warfarin and the novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban.
read on… or not…
We guarantee your privacy. Your email address will not be shared.
Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.
Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.
Includes a free 21 day trial of metajournal premium
We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.